Cellular and molecular biology of small cell lung cancer: an overview

被引：76

作者：

Karachaliou, Niki ^{[1
]}

Pilotto, Sara ^{[2
]}

Lazzari, Chiara ^{[3
]}

Bria, Emilio ^{[2
]}

de Marinis, Filippo ^{[3
]}

Rosell, Rafael ^{[1
,4
,5
,6
,7
]}

机构：

[1] Quiron Dexeus Univ Hosp, Inst Oncol Dr Rosell, Barcelona, Spain

[2] Univ Verona, Azienda Osped Univ Integrata, Dept Med Oncol, I-37100 Verona, Italy

[3] European Inst Oncol IEO, Div Thorac Oncol, Milan, Italy

[4] Pangaea Biotech, Barcelona, Spain

[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[6] Mol Oncol Res MORe Fdn, Barcelona, Spain

[7] Germans Trias & Pujol Hlth Sci Inst & Hosp, Campus Can Ruti, Badalona, Spain

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2016年 / 5卷 / 01期

关键词：

Small cell lung cancer (SCLC); targeted therapies; biomarkers; immune system; ACHAETE-SCUTE HOMOLOG-1; FIBROBLAST-GROWTH-FACTOR; STEM-CELLS; NEUROENDOCRINE TUMORS; THERAPEUTIC TARGET; MUTATIONAL LANDSCAPE; PROGNOSTIC-FACTOR; PHASE-II; EXPRESSION; CARCINOMA;

D O I：

10.3978/j.issn.2218-6751.2016.01.02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although the incidence of small cell lung cancer (SCLC) has declined during the past 30 years, it remains a frustrating disease to research and treat. Numerous attempts to enhance the anti-tumor effects of traditional chemotherapy for SCLC have not been successful. For any tumor to become cancerous, various genetic mutations and biologic alterations must occur in the cell that, when combined, render it a malignant neoplasm. New and novel therapies based on understanding these mechanisms of transformation are needed. Herein we provide an in-depth view of some of the genomic alterations in SCLC that have emerged as potential targets for therapeutic intervention.

引用

页码：2 / 15

页数：14

共 126 条

[51] Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer [J].

Jiang, Tianyun ;

Collins, Brendan J. ;

Jin, Ning ;

Watkins, David N. ;

Brock, Malcolm V. ;

Matsui, William ;

Nelkin, Barry D. ;

Ball, Douglas W. .

CANCER RESEARCH, 2009, 69 (03) :845-854

[52]

JOHNSON BE, 1988, CANCER RES, V48, P5163

[53] Two prognostically significant subtypes of high-grade lung neuroendocrine turnours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles [J].

Jones, MH ;

Virtanen, C ;

Honjoh, D ;

Miyoshi, T ;

Satoh, Y ;

Okumura, S ;

Nakagawa, K ;

Nomura, H ;

Ishikawa, Y .

LANCET, 2004, 363 (9411) :775-781

[54] Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPO-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide [J].

Karachaliou, Niki ;

Papadaki, Chara ;

Lagoudaki, Eleni ;

Trypaki, Maria ;

Sfakianaki, Maria ;

Koutsopoulos, Anastasios ;

Mavroudis, Dimitris ;

Stathopoulos, Efstathios ;

Georgoulias, Vassilis ;

Souglakos, John .

PLOS ONE, 2013, 8 (09)

[55] Identification of bronchioalveolar stem cells in normal lung and lung cancer [J].

Kim, CFB ;

Jackson, EL ;

Woolfenden, AE ;

Lawrence, S ;

Babar, I ;

Vogel, S ;

Crowley, D ;

Bronson, RT ;

Jacks, T .

CELL, 2005, 121 (06) :823-835

[56]

Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]

[57] FAK and PI3K/mTOR inhibitors target cancer stem cells: Implications for SCLC treatment strategies [J].

Kolev, Vihren N. ;

Xu, Qunli ;

Pachter, Jonathan A. ;

Weaver, David T. .

CANCER RESEARCH, 2015, 75

[58] Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62Lhigh CD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage [J].

Koyama, Kenichi ;

Kagamu, Hiroshi ;

Miura, Satoru ;

Hiura, Toru ;

Miyabayashi, Takahiro ;

Itoh, Ryo ;

Kuriyama, Hideyuki ;

Tanaka, Hiroshi ;

Tanaka, Junta ;

Yoshizawa, Hirohisa ;

Nakata, Koh ;

Gejyo, Fumitake .

CLINICAL CANCER RESEARCH, 2008, 14 (21) :6770-6779

[59]

KREYBERG L, 1962, ACTA PATHOL MIC SC, P11

[60] Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin [J].

Krug, LM ;

Ragupathi, G ;

Hood, C ;

Kris, MG ;

Miller, VA ;

Allen, JR ;

Keding, SJ ;

Danishefsky, SJ ;

Gomez, J ;

Tyson, L ;

Pizzo, B ;

Baez, V ;

Livingston, PO .

CLINICAL CANCER RESEARCH, 2004, 10 (18) :6094-6100

← 1 2 3 4 5 6 7 8 9 10 →